Carolina Henkes Inamassu, Regina Sordi, Camila Marchioni
{"title":"Cannabinoids in preclinical research of sepsis: a scoping review.","authors":"Carolina Henkes Inamassu, Regina Sordi, Camila Marchioni","doi":"10.1007/s00011-025-02090-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sepsis is a global health problem that ends millions of lives and costs billions of dollars in treatment and management every year. This disease is responsible for one in every five deaths worldwide, and is the third leading cause of death in hospitals. Despite decades of research, no current specific treatment or cure are available, only supportive and symptomatic care, and few preclinical studies reach human trials. Since the discovery of the endocannabinoid system (ECS), cannabinoids have been researched as a potential treatment for various diseases, including sepsis. Our review aimed to summarize what is known about the endocannabinoid system research in preclinical sepsis.</p><p><strong>Methods: </strong>A scoping search was conducted in the databases Pubmed, Scopus and Web of Science. Articles were selected in case they studied a cannabinoid or the ECS in preclinical sepsis or septic shock, with no time limit. Data regarding animals species, model os sepsis, treatments, cannabinoids utilized and main outcomes were analyzed.</p><p><strong>Results: </strong>We found that the most commonly used animal species was both Mus musculus and Rattus norvegicus, and the most frequently performed sepsis model was the endotoxemia induced by lipopolysaccharide (LPS). The most studied receptor was cannabinoid receptor type 2 (CB2) and among all cannabinoid types, synthetic cannabinoids were researched in the majority of the studies. We also discuss the evaluated outcomes, as well as their involvement with the endocannabinoid system and underlying molecular mechanisms. We highlight the main promising results and explore the limitations and future challenges in the field.</p><p><strong>Conclusion: </strong>Cannabinoids are promising therapeutic targets in the treatment of sepsis, as they improved survival, and reduced inflammation and organ injury. However, deleterious adverse effects were reported, with the underlying molecular mechanisms still unknown, and further research is needed to evaluate their benefits and future use in clinical research.</p>","PeriodicalId":13550,"journal":{"name":"Inflammation Research","volume":"74 1","pages":"125"},"PeriodicalIF":5.4000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammation Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00011-025-02090-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Sepsis is a global health problem that ends millions of lives and costs billions of dollars in treatment and management every year. This disease is responsible for one in every five deaths worldwide, and is the third leading cause of death in hospitals. Despite decades of research, no current specific treatment or cure are available, only supportive and symptomatic care, and few preclinical studies reach human trials. Since the discovery of the endocannabinoid system (ECS), cannabinoids have been researched as a potential treatment for various diseases, including sepsis. Our review aimed to summarize what is known about the endocannabinoid system research in preclinical sepsis.
Methods: A scoping search was conducted in the databases Pubmed, Scopus and Web of Science. Articles were selected in case they studied a cannabinoid or the ECS in preclinical sepsis or septic shock, with no time limit. Data regarding animals species, model os sepsis, treatments, cannabinoids utilized and main outcomes were analyzed.
Results: We found that the most commonly used animal species was both Mus musculus and Rattus norvegicus, and the most frequently performed sepsis model was the endotoxemia induced by lipopolysaccharide (LPS). The most studied receptor was cannabinoid receptor type 2 (CB2) and among all cannabinoid types, synthetic cannabinoids were researched in the majority of the studies. We also discuss the evaluated outcomes, as well as their involvement with the endocannabinoid system and underlying molecular mechanisms. We highlight the main promising results and explore the limitations and future challenges in the field.
Conclusion: Cannabinoids are promising therapeutic targets in the treatment of sepsis, as they improved survival, and reduced inflammation and organ injury. However, deleterious adverse effects were reported, with the underlying molecular mechanisms still unknown, and further research is needed to evaluate their benefits and future use in clinical research.
背景:败血症是一个全球性的健康问题,每年夺去数百万人的生命,花费数十亿美元用于治疗和管理。全世界每五例死亡中就有一例是由这种疾病造成的,它是医院死亡的第三大原因。尽管经过数十年的研究,目前还没有具体的治疗或治愈方法,只有支持性和对症治疗,很少有临床前研究能达到人体试验。自从内源性大麻素系统(ECS)被发现以来,大麻素已被研究作为各种疾病的潜在治疗方法,包括败血症。我们的综述旨在总结内源性大麻素系统在临床前败血症中的研究进展。方法:在Pubmed、Scopus和Web of Science数据库中进行检索。文章选择的情况下,他们研究大麻素或ECS在临床前败血症或感染性休克,没有时间限制。分析了动物种类、脓毒症模型、治疗方法、大麻素使用和主要结局的数据。结果:我们发现最常用的动物种类是小家鼠和褐家鼠,最常用的脓毒症模型是脂多糖(LPS)诱导的内毒素血症。研究最多的受体是大麻素受体2型(CB2),在所有大麻素类型中,合成大麻素的研究居多。我们还讨论了评估结果,以及它们与内源性大麻素系统和潜在分子机制的关系。我们强调了主要的有希望的结果,并探讨了该领域的局限性和未来的挑战。结论:大麻素可以提高脓毒症患者的存活率,减少炎症和器官损伤,是治疗脓毒症的理想靶点。然而,有害的不良反应已被报道,其潜在的分子机制尚不清楚,需要进一步的研究来评估其益处和未来在临床研究中的应用。
期刊介绍:
Inflammation Research (IR) publishes peer-reviewed papers on all aspects of inflammation and related fields including histopathology, immunological mechanisms, gene expression, mediators, experimental models, clinical investigations and the effect of drugs. Related fields are broadly defined and include for instance, allergy and asthma, shock, pain, joint damage, skin disease as well as clinical trials of relevant drugs.